NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Ticagrelor for the treatment of acute coronary syndromes (ACS)

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

No equalities issues were raised during the scoping process.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

No equalities issues were raised in any of the submission made during the course of the appraisal.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No equalities issues were identified by the Committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

No	
5.	Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?
N/a	
6.	Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
	equalities issues were identified by the Committee and this has been ed in the appraisal consultation document.
	23/06/11 I appraisal determination
1.	Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?
No e	equalities issues were identified during consultation.
2.	If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?
Nο	

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

N/A

4. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

No equalities issues were identified by the Committee and this has been stated in the FAD.

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 26 08 11